Compare STKE & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STKE | MGNX |
|---|---|---|
| Founded | 2002 | 2000 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.8M | 94.9M |
| IPO Year | N/A | 2013 |
| Metric | STKE | MGNX |
|---|---|---|
| Price | $2.60 | $1.37 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.20 |
| AVG Volume (30 Days) | 221.3K | ★ 1.2M |
| Earning Date | 01-29-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $14,342,517.00 | ★ $127,626,000.00 |
| Revenue This Year | $43.15 | N/A |
| Revenue Next Year | $39.60 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.07 | $0.99 |
| 52 Week High | $34.32 | $3.64 |
| Indicator | STKE | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 41.08 |
| Support Level | N/A | $1.33 |
| Resistance Level | N/A | $1.47 |
| Average True Range (ATR) | 0.00 | 0.10 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 0.00 | 14.63 |
Sol Strategies Inc is engaged in investing in blockchain technologies and crypto currencies. Company executes its Investment Objective through three lines of effort: Treasury management: Maintaining a core portfolio of cryptocurrencies for long-term growth, enhanced with risk management strategies to minimize volatility, and generating yield through lending, staking, and liquidity provisioning; Private equity focused on early stage companies in the DeFi and blockchain sectors; and Active investments to generate yield through strategic activities, including Bitcoin mining and stalking and validating Solana.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.